[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Treatment of Atrial Fibrillation

Educational Objective
To review the clinical management of atrial fibrillation.
1 Credit CME
Abstract

Importance  Atrial fibrillation is a common arrhythmia that affects more than 2.5 million people in the United States and causes substantial morbidity and mortality, especially regarding the increased risk of stroke.

Objective  To summarize atrial fibrillation treatment exclusive of stroke prevention.

Evidence Review  An Ovid MEDLINE comprehensive literature search was performed on atrial fibrillation therapy excluding anticoagulation and emphasizing studies published within the last 5 years through April 2015 (N = 5044 references). The 2014 atrial fibrillation guideline from the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society also was reviewed.

Findings  Reversible causes of atrial fibrillation should be identified. Risk factor modification, including weight loss and treatment of hypertension, diabetes, and obstructive sleep apnea can reduce atrial fibrillation episodes. Appropriate anticoagulation is necessary for patients at substantial stroke risk regardless of rate or rhythm treatment strategy. Sinus rhythm is often needed to control symptoms; however, an alternative strategy for atrial fibrillation is appropriate rate control. Rate control is safe in older patients (those who are about age ≥65 years) followed up for a few years, but no such safety data exist for patients younger than 60 years or for those followed up for longer periods. Thus, selection of therapy is individualized, taking into account present and future medical problems for the patient. Choice of an antiarrhythmic drug is based on safety first vs efficacy. Catheter ablation is an effective nonpharmacological alternative that is often, but not always, the second-line treatment. Reduction of the frequency and duration of atrial fibrillation episodes that result in a significant improvement in quality of life is a good marker of drug treatment success and complete elimination of atrial fibrillation is not required in many patients. Rate control is usually achieved with a β-blocker or non–dihydropyridine calcium channel blockers. It is important to assess adequate rate control during both rest and activity. If the ventricular rate goes uncontrolled for a prolonged period, tachycardia-mediated cardiomyopathy can occur.

Conclusions and Relevance  Therapy for atrial fibrillation includes prevention and modification of inciting causes and appropriate anticoagulation. Rate control is necessary for all patients. Maintenance of sinus rhythm with drugs or catheter ablation should be considered based on the individual needs of each patient.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Eric N. Prystowsky, MD, St Vincent Medical Group, 8333 Naab Rd, Indianapolis, IN 46260 (enprysto@stvincent.org).

Author Contributions: Dr Prystowsky had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: All authors.

Acquisition, analysis, or interpretation of data: Prystowsky.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: All authors.

Study supervision: Prystowsky.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Prystowsky reported receiving personal fees for serving on the board of directors for Stereotaxis; previously serving on the board of directors for CardioNet; owning stock in Stereotaxis; previously owning stock in CardioNet and Topera; receiving personal fees for serving as a consultant to Abbott, EP/Topera, CardioNet, Stereotaxis, and Medtronic; receiving institutional grant support from Boston Scientific, Medtronic, and St Jude; and holding a patent with CardioNet but not receiving royalties. Dr Padanilam reported owning stock in Topera. No other disclosures were reported.

References
1.
Prystowsky  EN, Padanilam  BJ, Waldo  AL. Atrial fibrillation, atrial flutter, and atrial tachycardia. In: Fuster  V, Walsh  RA, Harrington  RA,  et al, eds.  Hurst’s The Heart. 13th ed. New York, NY: McGraw Hill; 2011:963-986.
2.
January  CT, Wann  LS, Alpert  JS,  et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2014;130(23):e272-e274].  Circulation. 2014;130(23):e199-e267. PubMedGoogle ScholarCrossref
3.
Lip  GY, Lane  DA.  Stroke prevention in atrial fibrillation: a systematic review.  JAMA. 2015;313(19):1950-1962.PubMedGoogle ScholarCrossref
4.
Packer  DL, Bardy  GH, Worley  SJ,  et al.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.  Am J Cardiol. 1986;57(8):563-570.PubMedGoogle ScholarCrossref
5.
Nerheim  P, Birger-Botkin  S, Piracha  L, Olshansky  B.  Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia.  Circulation. 2004;110(3):247-252.PubMedGoogle ScholarCrossref
6.
Shen  MJ, Choi  EK, Tan  AY,  et al.  Neural mechanisms of atrial arrhythmias.  Nat Rev Cardiol. 2012;9(1):30-39.PubMedGoogle ScholarCrossref
7.
Nishida  K, Datino  T, Macle  L, Nattel  S.  Atrial fibrillation ablation: translating basic mechanistic insights to the patient.  J Am Coll Cardiol. 2014;64(8):823-831.PubMedGoogle ScholarCrossref
8.
Coumel  P, Attuel  P, Lavallée  J, Flammang  D, Leclercq  JF, Slama  R.  Syndrome d’arythmie auriculaire d’origine vagale [in French].  Arch Mal Coeur Vaiss. 1978;71(6):645-656.PubMedGoogle Scholar
9.
Scherf  D, Romano  FJ, Terranova  R.  Experimental studies on auricular flutter and auricular fibrillation.  Am Heart J. 1948;36(2):241-251.PubMedGoogle ScholarCrossref
10.
Cheung  DW.  Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig.  J Physiol. 1981;314:445-456.PubMedGoogle ScholarCrossref
11.
Haïssaguerre  M, Jaïs  P, Shah  DC,  et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.  N Engl J Med. 1998;339(10):659-666.PubMedGoogle ScholarCrossref
12.
Moe  GK, Rheinboldt  WC, Abildskov  JA.  A computer model of atrial fibrillation.  Am Heart J. 1964;67:200-220.PubMedGoogle ScholarCrossref
13.
Nattel  S, Harada  M.  Atrial remodeling and atrial fibrillation: recent advances and translational perspectives.  J Am Coll Cardiol. 2014;63(22):2335-2345.PubMedGoogle ScholarCrossref
14.
Narayan  SM, Krummen  DE, Rappel  WJ.  Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation.  J Cardiovasc Electrophysiol. 2012;23(5):447-454.PubMedGoogle ScholarCrossref
15.
Narayan  SM, Krummen  DE, Shivkumar  K, Clopton  P, Rappel  WJ, Miller  JM.  Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial.  J Am Coll Cardiol. 2012;60(7):628-636.PubMedGoogle ScholarCrossref
16.
Abed  HS, Wittert  GA, Leong  DP,  et al.  Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.  JAMA. 2013;310(19):2050-2060.PubMedGoogle ScholarCrossref
17.
Pathak  RK, Middeldorp  ME, Lau  DH,  et al.  Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study.  J Am Coll Cardiol. 2014;64(21):2222-2231.PubMedGoogle ScholarCrossref
18.
Pathak  TK, Middeldorp  ME, Meredith  M,  et al.  Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY).  J Am Coll Cardiol. 2015;65(20):2159–2169.Google ScholarCrossref
19.
Wazni  OM, Marrouche  NF, Martin  DO,  et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.  JAMA. 2005;293(21):2634-2640.PubMedGoogle ScholarCrossref
20.
Jaïs  P, Cauchemez  B, Macle  L,  et al.  Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study.  Circulation. 2008;118(24):2498-2505.PubMedGoogle ScholarCrossref
21.
Wilber  DJ, Pappone  C, Neuzil  P,  et al; ThermoCool AF Trial Investigators.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.  JAMA. 2010;303(4):333-340.PubMedGoogle ScholarCrossref
22.
Packer  DL, Kowal  RC, Wheelan  KR,  et al; STOP AF Cryoablation Investigators.  Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial.  J Am Coll Cardiol. 2013;61(16):1713-1723.PubMedGoogle ScholarCrossref
23.
Cosedis Nielsen  J, Johannessen  A, Raatikainen  P,  et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.  N Engl J Med. 2012;367(17):1587-1595.PubMedGoogle ScholarCrossref
24.
Mont  L, Bisbal  F, Hernández-Madrid  A,  et al; SARA investigators.  Catheter ablation vs antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study).  Eur Heart J. 2014;35(8):501-507.PubMedGoogle ScholarCrossref
25.
Morillo  CA, Verma  A, Connolly  SJ,  et al; RAAFT-2 Investigators.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.  JAMA. 2014;311(7):692-700.PubMedGoogle ScholarCrossref
26.
Wyse  DG, Waldo  AL, DiMarco  JP,  et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators.  A comparison of rate control and rhythm control in patients with atrial fibrillation.  N Engl J Med. 2002;347(23):1825-1833.PubMedGoogle ScholarCrossref
27.
Van Gelder  IC, Hagens  VE, Bosker  HA,  et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.  N Engl J Med. 2002;347(23):1834-1840.PubMedGoogle ScholarCrossref
28.
Al-Khatib  SM, Allen LaPointe  NM, Chatterjee  R,  et al.  Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review.  Ann Intern Med. 2014;160(11):760-773.PubMedGoogle ScholarCrossref
29.
Chatterjee  S, Sardar  P, Lichstein  E, Mukherjee  D, Aikat  S.  Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis.  Pacing Clin Electrophysiol. 2013;36(1):122-133.PubMedGoogle ScholarCrossref
30.
Ionescu-Ittu  R, Abrahamowicz  M, Jackevicius  CA,  et al.  Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation.  Arch Intern Med. 2012;172(13):997-1004.PubMedGoogle ScholarCrossref
31.
Prystowsky  EN, Padanilam  BJ.  Preserve the brain: primary goal in the therapy of atrial fibrillation.  J Am Coll Cardiol. 2013;62(6):540-542.PubMedGoogle ScholarCrossref
32.
Bunch  TJ, Weiss  JP, Crandall  BG,  et al.  Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia.  Heart Rhythm. 2010;7(4):433-437.PubMedGoogle ScholarCrossref
33.
Soliman  EZ, Safford  MM, Muntner  P,  et al.  Atrial fibrillation and the risk of myocardial infarction.  JAMA Intern Med. 2014;174(1):107-114.PubMedGoogle ScholarCrossref
34.
Trulock  KM, Narayan  SM, Piccini  JP.  Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation.  J Am Coll Cardiol. 2014;64(7):710-721.PubMedGoogle ScholarCrossref
35.
Roy  D, Talajic  M, Nattel  S,  et al; Atrial Fibrillation and Congestive Heart Failure Investigators.  Rhythm control versus rate control for atrial fibrillation and heart failure.  N Engl J Med. 2008;358(25):2667-2677.PubMedGoogle ScholarCrossref
36.
Hsu  LF, Jaïs  P, Sanders  P,  et al.  Catheter ablation for atrial fibrillation in congestive heart failure.  N Engl J Med. 2004;351(23):2373-2383.PubMedGoogle ScholarCrossref
37.
Gentlesk  PJ, Sauer  WH, Gerstenfeld  EP,  et al.  Reversal of left ventricular dysfunction following ablation of atrial fibrillation.  J Cardiovasc Electrophysiol. 2007;18(1):9-14.PubMedGoogle ScholarCrossref
38.
Fuster  V, Rydén  LE, Cannom  DS,  et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in J Am Coll Cardiol. 2007;50(6):562].  J Am Coll Cardiol. 2006;48(4):854-906.PubMedGoogle ScholarCrossref
39.
Verma  A, Cairns  JA, Mitchell  LB,  et al; CCS Atrial Fibrillation Guidelines Committee.  2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.  Can J Cardiol. 2014;30(10):1114-1130.PubMedGoogle ScholarCrossref
40.
Prystowsky  EN.  The history of atrial fibrillation: the last 100 years.  J Cardiovasc Electrophysiol. 2008;19(6):575-582.PubMedGoogle ScholarCrossref
41.
Prystowsky  EN.  Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden cardiac death.  Am J Cardiol. 1996;78(8A):35-41.PubMedGoogle ScholarCrossref
42.
Calkins  H, Kuck  KH, Cappato  R,  et al; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.  Heart Rhythm. 2012;9(4):632-696.e21.PubMedGoogle ScholarCrossref
43.
Padanilam  BJ, Prystowsky  EN.  Ablation as first-line therapy for atrial fibrillation—not yet for all.  Card Electrophysiol Clin. 2012;3(4):299-304.Google ScholarCrossref
44.
Lin  WS, Tai  CT, Hsieh  MH,  et al.  Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy.  Circulation. 2003;107(25):3176-3183.PubMedGoogle ScholarCrossref
45.
Jalife  J, Berenfeld  O, Mansour  M.  Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation.  Cardiovasc Res. 2002;54(2):204-216.PubMedGoogle ScholarCrossref
46.
Nademanee  K, McKenzie  J, Kosar  E,  et al.  A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate.  J Am Coll Cardiol. 2004;43(11):2044-2053.PubMedGoogle ScholarCrossref
47.
Katritsis  DG, Pokushalov  E, Romanov  A,  et al.  Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial.  J Am Coll Cardiol. 2013;62(24):2318-2325.PubMedGoogle ScholarCrossref
48.
Narayan  SM, Baykaner  T, Clopton  P,  et al.  Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation).  J Am Coll Cardiol. 2014;63(17):1761-1768.PubMedGoogle ScholarCrossref
49.
Haissaguerre  M, Hocini  M, Denis  A,  et al.  Driver domains in persistent atrial fibrillation.  Circulation. 2014;130(7):530-538.PubMedGoogle ScholarCrossref
50.
Piccini  JP, Lopes  RD, Kong  MH, Hasselblad  V, Jackson  K, Al-Khatib  SM.  Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials.  Circ Arrhythm Electrophysiol. 2009;2(6):626-633.PubMedGoogle ScholarCrossref
51.
Brooks  AG, Stiles  MK, Laborderie  J,  et al.  Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review.  Heart Rhythm. 2010;7(6):835-846.PubMedGoogle ScholarCrossref
52.
Ganesan  AN, Shipp  NJ, Brooks  AG,  et al.  Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis.  J Am Heart Assoc. 2013;2(2):e004549.PubMedGoogle ScholarCrossref
53.
Khan  AR, Khan  S, Sheikh  MA, Khuder  S, Grubb  B, Moukarbel  GV.  Catheter ablation and antiarrhythmic drug therapy as first- or second-line therapy in the management of atrial fibrillation: systematic review and meta-analysis.  Circ Arrhythm Electrophysiol. 2014;7(5):853-860.PubMedGoogle ScholarCrossref
54.
ClinicalTrials.gov. NCT00911508: Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA). https://clinicaltrials.gov/ct2/search/advanced. Accessibility verified June 16, 2015.
55.
ClinicalTrials.gov. NCT01288352: Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST). https://clinicaltrials.gov/ct2/search/advanced. Accessibility verified June 16, 2015.
56.
Cappato  R, Calkins  H, Chen  SA,  et al.  Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.  Circ Arrhythm Electrophysiol. 2010;3(1):32-38.PubMedGoogle ScholarCrossref
57.
Botto  GL, Politi  A, Bonini  W, Broffoni  T, Bonatti  R.  External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements.  Heart. 1999;82(6):726-730.PubMedGoogle ScholarCrossref
58.
Mittal  S, Ayati  S, Stein  KM,  et al.  Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks.  Circulation. 2000;101(11):1282-1287.PubMedGoogle ScholarCrossref
59.
Page  RL, Kerber  RE, Russell  JK,  et al; BiCard Investigators.  Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial.  J Am Coll Cardiol. 2002;39(12):1956-1963.PubMedGoogle ScholarCrossref
60.
Oral  H, Souza  JJ, Michaud  GF,  et al.  Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment.  N Engl J Med. 1999;340(24):1849-1854.PubMedGoogle ScholarCrossref
61.
Gallagher  MM, Guo  XH, Poloniecki  JD, Guan Yap  Y, Ward  D, Camm  AJ.  Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter.  J Am Coll Cardiol. 2001;38(5):1498-1504.PubMedGoogle ScholarCrossref
62.
Alboni  P, Botto  GL, Baldi  N,  et al.  Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach.  N Engl J Med. 2004;351(23):2384-2391.PubMedGoogle ScholarCrossref
63.
Gallagher  MM, Hennessy  BJ, Edvardsson  N,  et al.  Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion.  J Am Coll Cardiol. 2002;40(5):926-933.PubMedGoogle ScholarCrossref
64.
Olshansky  B, Rosenfeld  LE, Warner  AL,  et al; AFFIRM Investigators.  The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation.  J Am Coll Cardiol. 2004;43(7):1201-1208.PubMedGoogle ScholarCrossref
65.
Gillis  AM, Verma  A, Talajic  M, Nattel  S, Dorian  P; CCS Atrial Fibrillation Guidelines Committee.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.  Can J Cardiol. 2011;27(1):47-59.PubMedGoogle ScholarCrossref
66.
Kotecha  D, Holmes  J, Krum  H,  et al; β-Blockers in Heart Failure Collaborative Group.  Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.  Lancet. 2014;384(9961):2235-2243.PubMedGoogle ScholarCrossref
67.
Khand  AU, Rankin  AC, Martin  W, Taylor  J, Gemmell  I, Cleland  JG.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?  J Am Coll Cardiol. 2003;42(11):1944-1951.PubMedGoogle ScholarCrossref
68.
Turakhia  MP, Santangeli  P, Winkelmayer  WC,  et al.  Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study.  J Am Coll Cardiol. 2014;64(7):660-668.PubMedGoogle ScholarCrossref
69.
Wood  MA, Brown-Mahoney  C, Kay  GN, Ellenbogen  KA.  Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis.  Circulation. 2000;101(10):1138-1144.PubMedGoogle ScholarCrossref
70.
Curtis  AB, Worley  SJ, Adamson  PB,  et al; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators.  Biventricular pacing for atrioventricular block and systolic dysfunction.  N Engl J Med. 2013;368(17):1585-1593.PubMedGoogle ScholarCrossref
71.
Brignole  M, Botto  G, Mont  L,  et al.  Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial.  Eur Heart J. 2011;32(19):2420-2429.PubMedGoogle ScholarCrossref
72.
Ozcan  C, Jahangir  A, Friedman  PA,  et al.  Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation.  J Am Coll Cardiol. 2002;40(1):105-110.PubMedGoogle ScholarCrossref
73.
Grogan  M, Smith  HC, Gersh  BJ, Wood  DL.  Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.  Am J Cardiol. 1992;69(19):1570-1573.PubMedGoogle ScholarCrossref
74.
Van Gelder  IC, Wyse  DG, Chandler  ML,  et al; RACE and AFFIRM Investigators.  Does intensity of rate-control influence outcome in atrial fibrillation? an analysis of pooled data from the RACE and AFFIRM studies.  Europace. 2006;8(11):935-942.PubMedGoogle ScholarCrossref
75.
Van Gelder  IC, Groenveld  HF, Crijns  HJGM,  et al; RACE II Investigators.  Lenient versus strict rate control in patients with atrial fibrillation.  N Engl J Med. 2010;362(15):1363-1373.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements